CRYOPORT, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
CRYOPORT, INC. (CYRX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.05 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-09
- CRYOPORT, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$405.77K.
- CRYOPORT, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$641.28K.
- CRYOPORT, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$396.47K.
- CRYOPORT, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$72.34K.
- CRYOPORT, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$1.12M.
- CRYOPORT, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$70.13K.
- CRYOPORT, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$138.89K.
- CRYOPORT, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$178.68K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$405.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$1.05M 10-Q · filed 2017-08-09 | -$1.44M derived: sum of 3 quarters · filed 2017-08-09 | -$1.52M derived: sum of 4 quarters · filed 2017-08-09 |
| 2017-03-31 | -$641.28K 10-Q · filed 2017-05-04 | -$1.04M derived: sum of 2 quarters · filed 2017-05-04 | -$1.11M derived: sum of 3 quarters · filed 2017-05-04 | -$1.30M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-12-31 | -$396.47K derived: 10-KT 9 month − 10-Q 6 month · filed 2017-03-13 | -$468.81K derived: sum of 2 quarters · filed 2017-03-13 | -$662.67K 10-KT · filed 2017-03-13 | -$1.07M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-09-30 | -$72.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-11-14 | -$266.20K 10-Q · filed 2016-11-14 | -$671.46K derived: sum of 3 quarters · filed 2017-05-04 | -$1.05M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-06-30 | -$193.86K 10-Q · filed 2016-08-15 | -$599.12K 10-Q · filed 2017-08-09 | -$977.71K derived: sum of 3 quarters · filed 2017-05-04 | -$1.20M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-03-31 | -$405.26K 10-Q · filed 2017-05-04 | -$783.85K derived: sum of 2 quarters · filed 2017-05-04 | -$1.01M derived: sum of 3 quarters · filed 2017-05-04 | -$1.12M 10-KT · filed 2017-03-13 |
| 2015-12-31 | -$378.59K derived: 10-KT 9 month − 10-Q 6 month · filed 2017-03-13 | -$604.38K derived: sum of 2 quarters · filed 2017-03-13 | -$713.99K 10-KT · filed 2017-03-13 | -$716.27K derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-09-30 | -$225.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-11-14 | -$335.40K 10-Q · filed 2016-11-14 | -$337.68K derived: sum of 3 quarters · filed 2016-11-14 | -$337.68K derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | -$109.61K 10-Q · filed 2016-08-15 | -$111.89K derived: sum of 2 quarters · filed 2016-08-15 | -$111.89K derived: sum of 3 quarters · filed 2016-08-15 | -$179.75K derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-03-31 | -$2.28K derived: 10-K 12 month − 10-Q 9 month · filed 2016-06-28 | -$2.28K derived: sum of 2 quarters · filed 2016-06-28 | -$70.13K derived: sum of 3 quarters · filed 2016-06-28 | -$70.13K 10-K · filed 2016-06-28 |
| 2014-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-02-11 | -$67.85K derived: sum of 2 quarters · filed 2016-02-11 | -$67.85K 10-Q · filed 2016-02-11 | -$67.20K derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-09-30 | -$67.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-11-16 | -$67.85K 10-Q · filed 2015-11-16 | -$67.20K derived: sum of 3 quarters · filed 2015-11-16 | -$69.24K derived: sum of 4 quarters · filed 2015-11-16 |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-06 | $655.00 derived: sum of 2 quarters · filed 2015-08-06 | -$1.39K derived: sum of 3 quarters · filed 2015-08-06 | -$7.63K derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-03-31 | $655.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-19 | -$1.39K derived: sum of 2 quarters · filed 2015-05-19 | -$7.63K derived: sum of 3 quarters · filed 2015-05-19 | -$138.89K 10-K · filed 2015-05-19 |
| 2013-12-31 | -$2.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-05 | -$8.28K derived: sum of 2 quarters · filed 2015-02-05 | -$139.54K 10-Q · filed 2015-02-05 | |
| 2013-09-30 | -$6.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-11-12 | -$137.50K 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | -$131.26K 10-Q · filed 2014-07-31 | |||
| 2013-03-31 | -$178.68K 10-K · filed 2014-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |